Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Year: 2025
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang, Yaxin Liu, Yuee Teng, Xiaojia Wang, Jing Cheng, Zhongsheng Tong, Tao Sun, Min Yan, Xin Zhou, Fanfan Li, Jianyun Nie, Zhi-Ming Shao, Changsheng Ye, Yongsheng Wang, Xiaohong Wu, Zhihua Li, Yudong Wu, Huihua Xiong, Hui Li, Lu Gan, Zhaofeng Niu, Juliang Zhang, Qingyuan Zhang, Yueyin Pan, Xinhong Wu, Yi Zhang, Weimin Xie, Yu Xiao, Jinnan Gao, Huadong Zhao, Yongmei Yin, Zhiying Qian, Sanyuan Sun, Hongwei Zhang, Kun Wang, Jinsong Lu, Yong Li, Xinshuai Wang, Xinfeng Yang, Yuting Wang, Quanren Wang, Erwei Song
Institutions: University of Electronic Science and Technology of China, Peking University Cancer Hospital, Sichuan Cancer Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Central South University, Hunan Cancer Hospital, Sun Yat-sen University Cancer Center, First Hospital of China Medical University, Henan University of Science and Technology, Zhejiang Cancer Hospital, First Affiliated Hospital of Henan University of Science and Technology, Wuhan Union Hospital, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Liaoning Cancer Hospital & Institute, Zhengzhou University, Henan Cancer Hospital, Chongqing University, Chongqing Cancer Hospital, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Fudan University, Fudan University Shanghai Cancer Center, Nanfang Hospital, Southern Medical University, Shandong Tumor Hospital, Jiangsu Hengrui Medicine (China), Wuxi Fourth People's Hospital, Hubei Cancer Hospital, Jiangxi Provincial Cancer Hospital, Tongji Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University, Yuncheng Central Hospital, Xijing Hospital, Air Force Medical University, Third Affiliated Hospital of Harbin Medical University, Army Medical University, Southwest Hospital, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Peking University Third Hospital, Tang Du Hospital, Jiangsu Cancer Hospital, Xuzhou Central Hospital, Zhongshan Hospital, Guangdong General Hospital, Shanghai Jiao Tong University, Renji Hospital, Guizhou Provincial People's Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Guangdong Innovative and Entrepreneurial Research Team Program, Jiangsu Hengrui Medicine, National Natural Science Foundation of China, Guangdong Science and Technology Department, Guangzhou Municipal Science and Technology Bureau, Guangzhou Science and Technology Program key projects, National Key Research and Development Program of China
OpenAlex ID: W4416589062